Annemans, L., Packard, C. J. , Briggs, A. and Ray, K. K. (2018) 'Highest risk-highest benefit' strategy: a pragmatic, cost-effective approach to targeting use of PCSK9 inhibitor therapies. European Heart Journal, 39(27), pp. 2546-2550. (doi: 10.1093/eurheartj/ehx710) (PMID:29236976) (PMCID:PMC6047410)
|
Text
154392.pdf - Published Version Available under License Creative Commons Attribution Non-commercial. 293kB |
Abstract
No abstract available.
Item Type: | Articles |
---|---|
Additional Information: | This work was supported by Regeneron Pharmaceuticals, Inc. and Sanofi. |
Status: | Published |
Refereed: | Yes |
Glasgow Author(s) Enlighten ID: | Briggs, Professor Andrew and Packard, Professor Chris |
Authors: | Annemans, L., Packard, C. J., Briggs, A., and Ray, K. K. |
College/School: | College of Medical Veterinary and Life Sciences > School of Cardiovascular & Metabolic Health College of Medical Veterinary and Life Sciences > School of Health & Wellbeing > Health Economics and Health Technology Assessment |
Journal Name: | European Heart Journal |
Publisher: | Oxford University Press |
ISSN: | 0195-668X |
ISSN (Online): | 1522-9645 |
Published Online: | 11 December 2017 |
Copyright Holders: | Copyright © 2017 The Authors |
First Published: | First published in European Heart Journal 39(27): 2546-2550 |
Publisher Policy: | Reproduced under a Creative Commons License |
University Staff: Request a correction | Enlighten Editors: Update this record